Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COVID-19 Strengthens Ties Between UK MHRA & NICE On Access To Innovation

Executive Summary

New partnerships forged between the UK medicines regulator and health technology assessment bodies during COVID-19 have resulted in an improved understanding of the benefits new drugs can bring to the NHS and how to manage their rapid introduction.

You may also be interested in...



And The UK's First 'Innovation Passport' Goes To... MSD's Rare Disease Drug Belzutifan

The MHRA is losing no time in getting its much heralded “new era” of medicines regulation up and running.

UK Vaunts 'New Era' In Drug Approvals

The UK regulator, the MHRA, has published guidance on its new integrated pathway for innovative drug approvals, which it says is intended to bring together partners including health technology assessment agencies, health care bodies and patient organizations to offer “sustained collaboration” with drug developers.

EMA, HTA Bodies & Payers Explore Common Ground On Use Of RWE

A technical workshop is planned for later this year to identify common “use cases” for real-world evidence that are important to the European Medicines Agency, health technology assessment bodies and payers. 

Topics

Latest News
UsernamePublicRestriction

Register

PS143988

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel